Pharmafile Logo
Pharmafocus logo
Advanced Search

ingelheim

Showing 5 posts of 5 posts found.

Ofev image

Boehringer eyes Ofev success in IPF and beyond

March 16, 2015
Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev

Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …

News
Ofev image

Boehringer gains EU approval for Ofev

January 19, 2015
Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev

The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …

News
Pradaxa image

Boehringer gets NICE nod for Pradaxa

December 16, 2014
Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin

NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …

News
Pradaxa image

NICE recommends new indication for troubled Pradaxa

October 31, 2014
Sales and Marketing Boehringer, NHS, NICE, Pradaxa, dabigatran, ingelheim, warfarin

NICE has recommended Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa for treating and preventing potentially-fatal blood clots in the legs …

News

Boehringer’s lung cancer drug gets EMA nod

September 29, 2014
Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib

The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024